The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has introduced new opportunities for clinical trial applications (CTAs), while the broader European regulatory landscape continues to evolve with initiatives like FAST-EU, targeting multinational clinical trials. How can sponsors effectively navigate these changes?
This session provides practical guidance for leveraging MHRA's new CTA framework while applying critical insights from EU-CTR implementation, considering a global strategy. We explore approaches for harmonising submissions across UK and EU regulatory systems, identifying potential challenges, and implementing proactive solutions. Through expert analysis, sponsors will gain a clear roadmap for maximizing efficiency and accelerating patient access to innovative treatments.